ArticleAsian Pacific journal of cancer prevention : APJCP2026
Diagnostic Value of Rabbit-Derived 47 kDa Epitope-Based Antibodies as a Detection and Evaluation Method for Bladder Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to generate polyclonal antibodies against the 47 kDa protein using rabbits, and to evaluate both the diagnostic and prognostic potential of this biomarker in patients with bladder cancer.
methodsRabbits were immunized intraperitoneally with epitope antigens of the 47 kDa protein over a period of four weeks. Serum was collected in the fifth week five for antibody isolation. The resulting polyclonal antibodies were employed to detect urinary biomarkers in patients with bladder cancer. Additionally, these antibodies were used to evaluate therapeutic response in patients undergoing trimodal therapy, based on the RECIST (Response Evaluation Criteria in Solid Tumors) criteria, using the dot blot technique.
resultsThe highest density value with the best dilution effectiveness of 18.27 was found at antibody dilution 1/105 and antigen 1/106. From the dot blot analysis, this study found that the sensitivity and specificity of this antibody are 98.7% and 100%, respectively. The 47 kDa protein showed a high significant difference between each cancer stage before and after chemotherapy (PD: 7.91±1.99; SD: -1.00±0.83, PR: -5.80±3.21 CR: -7.95±1.47; p= 0.000), with a negative correlation with RECIST Criteria (r: -0.833, p=0.000).
conclusionThe 47 kDa protein demonstrates strong diagnostic performance and may be utilized as a prognostic factor in bladder cancer patients who have undergone trimodal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.